The glucagon-like peptide-1 receptor agonist exenatide does not yield improvement in measures of Parkinson disease severity, ...

The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients.

Exenatide had no disease-modifying effects in a phase 3 trial Parkinson’s disease, despite earlier evidence from a phase 2 ...

A drug for treating diabetes similar to popular weight-loss medicines such as Ozempic did not show any benefits for people ...

Researchers concluded that the GLP-1RA showed no ability to slow disease progression in people living with Parkinson’s ...

Ozempic and other glucagon-like peptide-1 (GLP-1) agonists are a transformative new class of medicines for the treatment of ...

The National Institute for Nephrology Dialysis and Transplantation (NINDT) has planned a series of events to mark this ...

WEDNESDAY, Feb. 5, 2025 (HealthDay News) -- Hopes that GLP-1 drugs such as Ozempic and Wegovy could help slow Parkinson's disease have taken an hit. A new study found that a drug in the same class ...

The remarkable efficacy of new diabetes and weight loss medicines like Ozempic and Mounjaro have been one of the biggest health stories of recent years. Despite rising rates of diabetes and obesity, ...

Pediatricians Leverage Genetic Testing for Faster Diagnoses Health systems across the country are making it easier for primary care clinicians to order genetic tests for patients who may have ...

Treatment with exenatide, a GLP-1 receptor agonist, was comparable to placebo in slowing the rate of Parkinson’s disease progression over 96 weeks of treatment, according to a phase 3 study ...